Monthly Archives: April 2011


Healthcare 2011 and beyond: Part 2

Medicaid is a state-run program that helps pay medical costs for some people with limited income and resources and meet other eligibility requirements. Medicaid also offers benefits not normally covered by Medicare, like help with personal care and rides to doctor appointments. If you qualify for Medicaid in your state, you automatically qualify to get Extra Help paying for Medicare prescription drug coverage.

By |2019-12-26T12:54:00-05:00April 1st, 2011|Advocacy, News|

April 2011 clinical trials update

The phase III dose escalation study intended to answer questions about Gleevec blood levels has halted recruitment after failing to meet accrual goals, having recruited only five first-line GIST patients in 14 months. Informal discussions with Novartis Pharmaceuticals, the Sarcoma Alliance for Research through Collaboration (SARC) and the trial investigators provided some insight into the reasons for the change in status.

By |2019-11-08T11:00:41-05:00April 1st, 2011|Clinical Trials, News|

Dating with GIST: the who, what, when and just plain how? (Part 2)

The perilous world of dating can become even more complicated when you are living with cancer. This article is the second in a two part series on dating with a diagnosis of GIST. Part one, which was published in the February 2011 issue of the LRG newsletter featured experiences from three GIST survivors, Jason DeLorenzo, Eric Tan & Estelle Lecointe on the difficulties approaching the subject of GIST while dating. Part two covers tips on approaching the subject, a success story and new ways to meet people.

By |2019-12-26T12:46:29-05:00April 1st, 2011|News, Pediatric GIST|

Breaking News Update: TDM renews plasma testing

On April 21, 2010, the U.S. Food and Drug Administration (FDA) issued a warning letter to Novartis criticizing its promotion of blood level testing on its CML and GIST Alliance websites. As of September 30, 2010, Novartis terminated the CML and GIST Alliance programs which it had contracted with TDM Pharmaceutical Research, LLC. Since then, the Life Raft Group has been working tirelessly behind the scenes to try and resume this critical testing procedure as it has important potential for managing GIST patient care.

By |2019-04-08T09:08:13-04:00April 1st, 2011|News|
Go to Top